[{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"SFX-01","moa":"Nrf2","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"suPAR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"1","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Canadian Institute of Health Resources","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Canadian Institute of Health Resources","highestDevelopmentStatusID":"1","companyTruncated":"Arch Biopartners \/ Canadian Institute of Health Resources"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD. Arch Biopartners is developing a pipeline of new candidates that inhibit inflammation in the lungs, liver, and kidneys via D...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 07, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Undisclosed

                          Sponsor : Canadian Institute of Health Resources

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : U-M will collaborate with Walden Biosciences in connection with Dr. Hayek’s ongoing research in the area of suPAR and Walden will provide materials, data analysis, and may perform experiments to support the work, including the role of polymorphisms in ...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Undisclosed

                          Sponsor : University of Michigan

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : AI-generated target was identified through Benevolent Platform® and AstraZeneca's scientific expertise and rich datasets. The Benevolent Platform® predicted this novel target, which was subsequently biologically validated through AstraZeneca's rigorous...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 27, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Undisclosed

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          University of Rochester School of Medicine & Dentistry

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          University of Rochester School of Medicine & Dentistry

                          Country arrow
                          Cosmoprof India
                          Not Confirmed

                          Details : Under the agreement, Evgen will supply SFX-01 to support a potential future clinical trial led by University of Rochester Nephrology division chief Thu Le.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 18, 2020

                          Lead Product(s) : SFX-01

                          Therapeutic Area : Nephrology

                          Highest Development Status : Undisclosed

                          Sponsor : Evgen Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank